Latest news with #FDAapproved
Globe and Mail
4 days ago
- Business
- Globe and Mail
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, August 14, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" section of Palvella's website. To access the call by phone, please use this registration link, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at About Palvella Therapeutics Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication. Contact Information
Yahoo
4 days ago
- Business
- Yahoo
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, August 14, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" section of Palvella's website. To access the call by phone, please use this registration link, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at About Palvella Therapeutics Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication. Contact Information InvestorsWesley H. KaupinenFounder and CEO, Palvella MediaMarcy NanusManaging Partner, Trilon Advisors, LLCmnanus@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 1:00 p.m. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella TherapeuticsFounded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any Information InvestorsWesley H. KaupinenFounder and CEO, Palvella MediaMarcy NanusManaging Partner, Trilon Advisors, LLCmnanus@
Yahoo
02-08-2025
- Business
- Yahoo
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics
Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio. In June 2025, Supernus and Sage entered a definitive agreement for the acquisition, with Supernus offering $8.50 per share in cash (or an aggregate of $561m), plus a non-tradeable contingent value right of up to $3.50 per share, totalling $12 per share in cash, or $795m. The acquisition follows Sage's rejection of a $469m takeover offer from Biogen in January 2025, which was deemed significantly undervalued by Sage's board of directors. The acquisition brings Sage's US Food and Drug Administration (FDA)-approved Zurzuvae (zuranolone) capsules and a central nervous system discovery platform under Supernus' portfolio. Zurzuvae is intended for treating postpartum depression. The company expects to realise cost synergies of up to $200m annually and accretive financial results in 2026 due to the acquisition. Moelis & Company served as the exclusive financial advisor to Supernus, while Goldman Sachs advised Sage. Legal counsel for Supernus was provided by Saul Ewing, and Kirkland & Ellis represented Sage in the legal aspects of the transaction. Supernus Pharmaceuticals CEO and president Jack Khattar stated: 'Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue. 'With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026.' "Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-08-2025
- Business
- Yahoo
Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy
Abeona Therapeutics Inc. (NASDAQ:ABEO) is one of the stocks under $10 to buy now. On July 29, AscellaHealth announced its successful HUB partnership with Abeona Therapeutics in the pre- and post-launch commercialization of ZEVASKYN (prademagene zamikeracel), which is an FDA-approved cell-based gene therapy. The collaboration addresses the clinical, operational, and reimbursement needs of this novel autologous cell-based gene therapy by designing and executing patient-centric, end-to-end solutions. An outcome of this partnership was the development and launch of AbeonaAssist, which is a customized patient support program designed to provide a seamless experience for patients, caregivers, and healthcare providers. A close-up of a staff member counting pills in a pharmaceutical warehouse. ZEVASKYN is the first and only autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa/RDEB. Abeona Therapeutics Inc. (NASDAQ:ABEO) is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening diseases. While we acknowledge the potential of ABEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
